- Home
- DBVT vs CRDF Comparison
DBVT vs CRDF Comparison
Compare DBVT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- CRDF
- Stock Information
- Founded
- DBVT 2002
- CRDF 1999
- Country
- DBVT France
- CRDF United States
- Employees
- DBVT N/A
- CRDF N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBVT Health Care
- CRDF Health Care
- Exchange
- DBVT Nasdaq
- CRDF Nasdaq
- Market Cap
- DBVT 250.5M
- CRDF 233.5M
- IPO Year
- DBVT N/A
- CRDF N/A
- Fundamental
- Price
- DBVT $10.80
- CRDF $4.04
- Analyst Decision
- DBVT Buy
- CRDF Strong Buy
- Analyst Count
- DBVT 4
- CRDF 6
- Target Price
- DBVT $14.81
- CRDF $11.92
- AVG Volume (30 Days)
- DBVT 26.3K
- CRDF 1.4M
- Earning Date
- DBVT 07-29-2025
- CRDF 08-07-2025
- Dividend Yield
- DBVT N/A
- CRDF N/A
- EPS Growth
- DBVT N/A
- CRDF N/A
- EPS
- DBVT N/A
- CRDF N/A
- Revenue
- DBVT $3,497,000.00
- CRDF $587,000.00
- Revenue This Year
- DBVT $1,700.53
- CRDF N/A
- Revenue Next Year
- DBVT $535.67
- CRDF N/A
- P/E Ratio
- DBVT N/A
- CRDF N/A
- Revenue Growth
- DBVT N/A
- CRDF N/A
- 52 Week Low
- DBVT $2.21
- CRDF $2.01
- 52 Week High
- DBVT $12.78
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- DBVT 58.42
- CRDF 65.93
- Support Level
- DBVT $10.53
- CRDF $3.07
- Resistance Level
- DBVT $11.33
- CRDF $4.22
- Average True Range (ATR)
- DBVT 0.76
- CRDF 0.22
- MACD
- DBVT 0.14
- CRDF 0.08
- Stochastic Oscillator
- DBVT 65.90
- CRDF 87.35
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.